“We have shown that
in vitro treatment with cannabidiol (CBD, 2 h) enhances endothelial function in arteries from Zucker diabetic fatty (ZDF) rats, partly due to a cyclooxygenase (COX)-mediated mechanism.
The aim of the present study was to determine whether treatment with CBD
in vivo would also enhance endothelial function.
Conclusion and implications: Short-term
in vivo treatment with CBD improves
ex vivo endothelium-dependent vasorelaxation in mesenteric arteries from ZDF rats due to COX- or NO-mediated mechanisms, and leads to improvements in serum biomarkers.”
https://www.ncbi.nlm.nih.gov/pubmed/28572770
“In conclusion, this study has shown that a short
in vivo treatment protocol with CBD was associated with improvements in endothelium-dependent vasorelaxation in mesenteric arteries, and an improvement in the profile of cardiovascular and metabolic parameters. The current study supports the growing evidence that CBD may be beneficial against a number of problems associated with diabetes including inflammation, endothelial dysfunction, cardiomyopathy, retinal function, and neuropathic pain.”
http://journal.frontiersin.org/article/10.3389/fphar.2017.00248/full